Prognostic value of the TP53 Arg72Pro single-nucleotide polymorphism and susceptibility to medulloblastoma in a cohort of Brazilian patients

Journal of Neuro-Oncology

Volumn 110, Issue 1, 2012, Pages 49-57

  Carvalho, Raimundo M ^a,b   Pinto, Giovanny R ^c   Yoshioka, France K N ^c   Lima, Patrícia D L ^b   Souza, Carolina R T ^b   Guimarães, Adriana C ^b   Lamarão, Letícia M ^b   Rey, Juan A ^d   Burbano, Rommel R ^b  

^a Ophir Loyola Hospital   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^c FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Adjuvant therapy; Medulloblastomas; Prognosis; Risk; TP53 Arg72Pro SNP

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GENOMIC DNA; METHOTREXATE; PROTEIN P53; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; POLYMERASE CHAIN REACTION; RADIATION DOSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR VOLUME;

BRAZIL; CASE-CONTROL STUDIES; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MEDULLOBLASTOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866387257     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0950-0     Document Type: Article

References (41)

1. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A (2008) Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14(4):971-976. doi: 10.1158/1078-0432.CCR-07-2072
2. Brandes AA, Franceschi E, Tosoni A, Reni M, Gatta G, Vecht C, Kortmann RD (2009) Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol/Hematol 71(2):165-179. doi: 10.1016/j.critrevonc.2009.02.002
3. Grotzer MA, Janss AJ, Fung K, Biegel JA, Sutton LN, Rorke LB, Zhao H, Cnaan A, Phillips PC, Lee VM, Trojanowski JQ (2000) TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18(5):1027-1035
4. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27(10):1627-1636. doi: 10.1200/JCO.2008.17.9432
5. Pizem J, Cort A, Zadravec-Zaletel L, Popovic M (2005) Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol 31(4):422-428. doi: 10.1111/j.1365-2990.2005.00664.x
6. Ray A, Ho M, Ma J, Parkes RK, Mainprize TG, Ueda S, McLaughlin J, Bouffet E, Rutka JT, Hawkins CE (2004) A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 10(22):7613-7620. doi: 10.1158/1078-0432.CCR- 04-0499
7. Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C (2010) Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28(8):1345-1350. doi: 10.1200/JCO.2009.23.5952
8. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24(12):1924-1931. doi: 10.1200/JCO.2005.04.4974
9. Benard J, Douc-Rasy S, Ahomadegbe JC (2003) TP53 family members and human cancers. Hum Mutat 21(3):182-191. doi: 10.1002/humu.10172
10. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622-629. doi: 10.1002/humu.20495
11. Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28(35):5188-5196. doi: 10.1200/JCO.2010.31.1670
12. Lindsey JC, Hill RM, Megahed H, Lusher ME, Schwalbe EC, Cole M, Hogg TL, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC (2011) TP53 mutations in favorable-risk Wnt/wingless-subtype medulloblastomas. J Clin Oncol 29(12):e344-e346. doi: 10.1200/JCO.2010.33.8590
13. Gessi M, von Bueren AO, Rutkowski S, Pietsch T (2012) p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. J Neurooncol 106(1):135-141. doi: 10.1007/s11060-011-0648-8
14. Efeyan A, Serrano M (2007) p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6(9):1006-1010
15. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genet 33(3):357-365. doi: 10.1038/ng1093
16. Leu JI, Dumont P, Hafey M, Murphy ME, George DL (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6(5):443-450. doi: 10.1038/ncb1123
17. Almeida LO, Custodio AC, Pinto GR, Santos MJ, Almeida JR, Clara CA, Rey JA, Casartelli C (2009) Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. Genet Mol Res 8(1):8-18
18. El Hallani S, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, Laigle-Donadey F, Rodero M, Chinot O, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M (2009) TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology 72(4):332-336. doi: 10.1212/01.wnl.0000341277.74885.ec
19. Jha P, Jha P, Pathak P, Chosdol K, Suri V, Sharma MC, Kumar G, Singh M, Mahapatra AK, Sarkar C (2011) TP53 polymorphisms in gliomas from Indian patients: study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp Mol Pathol 90(2):167-172. doi: 10.1016/j.yexmp.2010. 11.002
20. Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H (2009) Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol 19(2):188-194. doi: 10.1111/j.1750-3639.2008.00170.x
21. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS, Strother DR, Burger PC (2002) Histopathologic grading of medulloblastomas: a Pediatric Oncology Group Study. Cancer 94(2):552-560. doi: 10.1002/cncr.10189
22. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97-109. doi: 10.1007/s00401-007-0243-4
23. Pinto GR, Yoshioka FK, Silva RL, Clara CA, Santos MJ, Almeida JR, Burbano RR, Rey JA, Casartelli C (2008) Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res 7(1):207-216
24. Feng Z, Levine AJ (2010) The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 20(7):427-434. doi: 10.1016/j.tcb.2010.03.004
25. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD (2003) Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 100(1):177-182. doi: 10.1073/pnas.0126614100
26. Biros E, Kalina I, Kohut A, Bogyiova E, Salagovic J, Sulla I (2002) Allelic and haplotype frequencies of the p53 polymorphisms in brain tumor patients. Physiol Res/Acad Sci Bohemoslov 51(1):59-64
27. Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW (2005) Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res 137(1-2):98-103. doi: 10.1016/j.molbrainres.2005.02.016
28. Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, Lopes JM, Reis RM (2008) TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet 180(1):14-19. doi: 10.1016/j.cancergencyto.2007.08.019
29. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A (2004) Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24(1):21-34. doi: 10.1002/humu.20055
30. Ray A, Ho M, Ma J, Parkes RK, Mainprize TG, Ueda S, McLaughlin J, Bouffet E, Rutka JT, Hawkins CE (2004) A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 22:7613-7620. doi: 10.1158/1078-0432.CCR-04- 0499
31. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408-1414. doi: 10.1200/JCO.2009.27.4324
32. Ellison DW (2010) Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol 3:305-316. doi: 10.1007/s00401-010-0726-6
33. von Hoff K, Hartmann W, von Bueren AO, Gerber NU, Grotzer MA, Pietsch T, Rutkowski S (2010) Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatr Blood Cancer 3:369-376. doi: 10.1002/pbc.22339
34. Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison DW, Garre ML, Biassoni V, Grundy RG, Finlay JL, Dhall G, Raquin MA, Grill J (2010) Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 33:4961-4968. doi: 10.1200/JCO.2010.30.2299
35. de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, Grajkowska W, Perek M, Osterheld MC, Ellison D, Baas F, Versteeg R, Kool M (2008) Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 13:4154-4160. doi: 10.1158/1078-0432.CCR-07-4159
36. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845
37. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS (2005) Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41:727-734. doi: 10.1016/j.ejca.2004.12.017
38. Pizer BL, Clifford SC (2009) The potential impact of tumor biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 23:364-375. doi: 10.1080/ 02688690903121807
39. Kweekel DM, Van der Straaten T, Koopman M, Meijer GA, Nortier JW, Cornelis JA, Gelderblom H, Guchelaar HJ (2010) Comparison of genetic polymorphisms in DNA isolated from blood and paraffin embedded colorectal cancer tissue. https://openaccess.leidenuniv.nl/bitstream/handle/1887/13820/03.pdf. Accessed 10 Feb 2012
40. Cerne JZ, Pohar-Perme M, Novakovic S, Frkovic-Grazio S, Stegel V, Gersak K (2011) Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer. J Gynecol Oncol 22(2):110-119. doi: 10.3802/jgo.2011.22.2.110
41. Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD (2003) Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 13(8):501-507. doi: 10.1097/00008571-200308000-00008